Evidence item

Disease control included confirmed complete response, partial response, or stable disease lasting at least four weeks. DIRECT_TEXT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 15122

Source: Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial · locator {} · excerpt hash sha256:88ca123744166fd91a72a3bf3466f301f0ddbed916ef73c915ca10282d36d172

DCR was the proportion of subjects with confirmed CR, PR and stable disease for at least 4 weeks.